Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assess...
Saved in:
Published in | ESMO open Vol. 9; no. 10; p. 103713 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.10.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient’s prognosis.
•Immune checkpoint inhibitors (ICIs) have not been adequately assessed in early triple-negative breast cancer (TNBC).•The window of opportunity (WOO) offers a niche to test ICIs alone or in combination and measure responses and biomarkers.•This article reviews and summarizes the results of different WOO trials with ICIs in TNBC.•Some patients responded very well to a few doses, allowing partial de-escalation of therapy without compromising prognosis. |
---|---|
AbstractList | Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient's prognosis.Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient's prognosis. Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient's prognosis. Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with chemotherapy is the current standard of care in TNBC patients with stage II and III. Monotherapy with ICIs has not been comprehensively assessed in the neoadjuvant setting in TNBC patients, given unfavorable results in metastatic trials. ICIs, however, have been tested in the window of opportunity (WOO) before surgery or standard chemotherapy-based neoadjuvant treatment. The WOO design is well suited to assess an ICI alone or in combination with other ICIs, targeted therapy, radiotherapy or cryotherapy, and measure their pharmacodynamic and clinical effect in this treatment-naive population. Some patients show a good response to ICIs in WOO studies. Biomarkers like tumor-infiltrating lymphocytes, programmed death ligand-1, and interferon-γ signature may predict activity and may identify patients likely to benefit from ICIs. Moreover, an increase in tumor-infiltrating lymphocytes, programmed death ligand-1 expression or T cell receptor expansion following administration of ICIs in the WOO setting could potentially inform of immunotherapy benefit, which would allow tailoring further treatment. This article reviews WOO trials that assessed immunotherapy in the early-stage TNBC population, and how these results could be translated to test de-escalation strategies of neoadjuvant chemotherapy and immunotherapy without compromising a patient’s prognosis. •Immune checkpoint inhibitors (ICIs) have not been adequately assessed in early triple-negative breast cancer (TNBC).•The window of opportunity (WOO) offers a niche to test ICIs alone or in combination and measure responses and biomarkers.•This article reviews and summarizes the results of different WOO trials with ICIs in TNBC.•Some patients responded very well to a few doses, allowing partial de-escalation of therapy without compromising prognosis. |
ArticleNumber | 103713 |
Author | Cortes, J. Peg, V. Vidal, L. Schmid, P. Slebe, F. Loibl, S. Quintana, A. Saini, K.S. Curigliano, G. |
Author_xml | – sequence: 1 givenname: A. orcidid: 0000-0002-6470-0802 surname: Quintana fullname: Quintana, A. email: quintana.angelam@gmail.com organization: Breast Cancer Unit, Vall d’Hebrón Institute of Oncology, Barcelona, Spain – sequence: 2 givenname: K.S. orcidid: 0000-0001-6301-3309 surname: Saini fullname: Saini, K.S. organization: Fortrea, Inc., Durham, USA – sequence: 3 givenname: L. surname: Vidal fullname: Vidal, L. organization: Fortrea, Inc., Durham, USA – sequence: 4 givenname: V. orcidid: 0000-0002-5203-6166 surname: Peg fullname: Peg, V. organization: Biomedical Research Network Centre in Oncology (CIBERONC), Madrid – sequence: 5 givenname: F. surname: Slebe fullname: Slebe, F. organization: Medica Scientia Innovation Research (MedSIR), Barcelona, Spain – sequence: 6 givenname: S. surname: Loibl fullname: Loibl, S. organization: German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany – sequence: 7 givenname: G. orcidid: 0000-0003-1781-2518 surname: Curigliano fullname: Curigliano, G. organization: European Institute of Oncology, IRCCS, Milan – sequence: 8 givenname: P. surname: Schmid fullname: Schmid, P. organization: Barts Cancer Institute, Queen Mary University London, London, UK – sequence: 9 givenname: J. orcidid: 0000-0001-7623-1583 surname: Cortes fullname: Cortes, J. organization: Medica Scientia Innovation Research (MedSIR), Barcelona, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39357122$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1rGzEQhkVIaZw0_6AEHXtZV1-78l4CJeSjYOilpUehlWZjuV5pK2lt8u8js07JqacZhmdmeJ9LdO6DB4Q-U7KkhDZft0tIQwjjkhEmyohLys_QgpG6rSRh7fm7_gJdp7QlhFApyrD5iC54y2tJGVsg9dt5Gw449DiMY4h58i6_4Byd3iV8cHmD3TBMHrDZgPkzBuczdn7jOpdDTKU9suMOKg_POrs94C6CThkb7Q3ET-hDXy7B9aleoV8P9z_vnqr1j8fvd9_WlSkJeMVr25Fer4Aw2hphWt2R1lLTgBU1ZUS0xHZ1y6nUsq6NIKBpI4WVHawM71f8Cn2Z744x_J0gZTW4ZGC30x7ClBSnlNWsEUwWVMyoiSGlCL0aoxt0fFGUqKNdtVWzXXW0q2a7Ze3m9GHqBrD_lt5cFuB2BqDk3DuIKhkHRYJ1EUxWNrj_f3gFW8mPxQ |
Cites_doi | 10.1016/j.ejca.2024.113952 10.1001/jamaoncol.2023.5033 10.1200/JCO.2023.41.16_suppl.573 10.1016/j.annonc.2022.01.009 10.1016/j.annonc.2020.05.015 10.1016/j.medj.2024.01.015 10.1182/bloodadvances.2020001797 10.1158/1538-7445.SABCS20-PS12-09 10.1200/JCO.2023.41.16_suppl.1011 10.1186/s40425-018-0428-5 10.1158/1538-7445.SABCS21-PD15-08 10.1093/annonc/mdx766 10.1016/j.annonc.2023.11.018 10.1200/JCO.2020.38.15_suppl.TPS598 10.1016/S1470-2045(20)30754-3 10.1016/j.annonc.2022.11.005 10.1001/jamaoncol.2019.6650 10.1093/annonc/mdz097.014 10.1200/JCO.2024.42.17_suppl.LBA501 10.1056/NEJMoa2112651 10.1200/JCO.2017.35.15_suppl.556 10.1016/j.annonc.2022.07.1940 10.1038/s41523-021-00362-1 10.1200/JCO.2014.58.1967 10.1200/JCO.2023.41.16_suppl.595 10.1200/JCO.2023.41.16_suppl.507 10.1016/j.annonc.2020.01.072 10.1016/j.annonc.2022.02.004 10.3389/fonc.2023.1200646 10.1200/JCO.2023.41.16_suppl.604 10.1200/JCO.2017.35.15_suppl.1008 10.1093/annonc/mdz158 10.1200/JCO.2011.38.2010 10.1056/NEJMoa1910549 10.1038/s41591-018-0198-0 10.1200/JCO.2014.57.0572 10.3390/ijms19123793 10.1186/2051-1426-2-S3-P138 10.1158/1078-0432.CCR-21-3215 10.1158/1538-7445.SABCS18-P2-09-07 10.1016/j.annonc.2023.10.008 10.1158/1538-7445.SABCS21-P2-08-23 10.1093/annonc/mdy399 10.1016/j.jtho.2021.08.075 10.1200/JCO.2024.42.17_suppl.LBA500 10.1200/JCO.2015.64.8931 10.1200/jco.2014.32.15_suppl.1098 10.3389/fonc.2021.803050 10.1016/j.semcancer.2017.10.003 10.1158/1078-0432.CCR-16-0190 10.1056/NEJMoa1612645 10.1016/S0140-6736(20)31953-X 10.1001/jamaoncol.2018.4224 10.1200/JCO.2013.55.0491 10.1007/s10549-017-4537-5 10.1016/j.ejca.2021.01.037 10.1056/NEJMoa2105215 10.1093/annonc/mdy517 10.1001/jamaoncol.2019.0393 10.1186/s13058-015-0669-x 10.1093/annonc/mdy518 10.1038/s41591-019-0432-4 10.1158/2326-6066.CIR-16-0013 10.1158/1538-7445.SABCS18-PD2-07 10.1016/j.ccell.2023.01.004 10.1038/s41591-021-01323-8 10.1016/j.annonc.2022.08.007 |
ContentType | Journal Article |
Copyright | 2024 The Author(s) Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
Copyright_xml | – notice: 2024 The Author(s) – notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.esmoop.2024.103713 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2059-7029 |
ExternalDocumentID | 10_1016_j_esmoop_2024_103713 39357122 S2059702924014832 |
Genre | Journal Article Review |
GroupedDBID | .1- .FO 0R~ 0SF 53G 5VS 6I. 9YT AAEDW AAFTH AALRI AAXUO ACGFS ACMMV ADBBV ADRAZ ADVLN AFJKZ AFRHN AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BCNDV EBS FDB GROUPED_DOAJ HYE KQ8 M48 M~E O9- OK1 RHI ROL RPM Z5R NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c2023-35db0fa8e0219c4c9ab09d1c6ed45120490db59317a755c40ea1674d7be8c3f83 |
ISSN | 2059-7029 |
IngestDate | Thu Oct 03 17:34:11 EDT 2024 Wed Oct 16 15:13:39 EDT 2024 Tue Oct 15 08:52:45 EDT 2024 Sat Oct 05 15:37:21 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | PD-L1 tumor-infiltrating lymphocytes triple-negative breast cancer immune checkpoint inhibitors window of opportunity |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2023-35db0fa8e0219c4c9ab09d1c6ed45120490db59317a755c40ea1674d7be8c3f83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0002-5203-6166 0000-0001-7623-1583 0000-0002-6470-0802 0000-0001-6301-3309 0000-0003-1781-2518 |
OpenAccessLink | http://dx.doi.org/10.1016/j.esmoop.2024.103713 |
PMID | 39357122 |
PQID | 3112526427 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3112526427 crossref_primary_10_1016_j_esmoop_2024_103713 pubmed_primary_39357122 elsevier_sciencedirect_doi_10_1016_j_esmoop_2024_103713 |
PublicationCentury | 2000 |
PublicationDate | October 2024 2024-Oct-01 2024-10-00 20241001 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | ESMO open |
PublicationTitleAlternate | ESMO Open |
PublicationYear | 2024 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Spears, Hopkins, Keyhanian (bib58) 2023; 41 Césaire, Thariat, Candéias (bib20) 2018; 19 Gianni, Huang, Egle (bib37) 2022; 33 Czajka-Francuz, Prendes, Mankan (bib56) 2023; 13 Turner, Swift, Jenkins (bib66) 2023; 34 Winer, Lipatov, Im (bib6) 2021; 22 Loibl, Untch, Burchardi (bib17) 2019; 30 Schmid, Cortes, Dent (bib2) 2022; 386 Tutt, Garber, Kaufman (bib3) 2021; 384 Pan, Yu, Tang (bib71) 2024; 5 Mittendorf, Zhang, Barrios (bib38) 2020; 396 Loibl, Jackisch, Rastogi (bib40) 2019; 30 McArthur, Basho, Shiao (bib57) 2019; 79 Virassamy, Caramia, Savas (bib74) 2023; 41 Bear, Deng, Bandyopadhyay (bib43) 2024; 84 (bib34) 2024 Arnaout, Bender, Hopkins (bib54) 2024; 84 Pusztai, Barlow, Ganz (bib65) 2018; 78 Schmid, Salgado, Park (bib23) 2020; 31 Masuda, Lee, Ohtani (bib4) 2017; 376 Das, O’Connor, Grupp, Barrett (bib16) 2020; 4 Karn, Denkert, Weber (bib29) 2020; 31 Verma, Foster, Horgan (bib15) 2016; 18 Schmid, Park, Muñoz-Couselo (bib67) 2017; 35 Schmid, Cortés, Dent (bib33) 2023; 34 Kolberg, Schumacher, Erber (bib76) 2024; 84 Voorwerk, Slagter, Horlings (bib59) 2019; 25 Schmid, Park, Muñoz-Couselo (bib28) 2021; 9 Yang, Forbes, Bitting (bib48) 2018; 29 McArthur, Bailey, Saji (bib63) 2024; 200 Page, McArthur, Dong (bib69) 2014; 2 Spring, Tolaney, Fell (bib36) 2024; 35 McArthur, Diab, Page (bib42) 2016; 22 McArthur, Shiao, Karlan (bib27) 2021; 81 Loi, Salgado, Adams (bib22) 2022; 8 Loibl, Sinn, Karn (bib30) 2019; 79 Conte, Dieci, Bisagni (bib39) 2024; 42 Page, Su, Moxon (bib41) 2023; 41 Stecklein, Yoder, Staley (bib25) 2023; 41 Nederlof, Isaeva, Bakker (bib19) 2022; 33 Denkert, von Minckwitz, Brase (bib50) 2015; 33 Loibl, Schneeweiss, Huober (bib18) 2022; 33 Geyer, Sikov, Huober (bib51) 2022; 33 Sharma, Stecklein, Yoder (bib24) 2024; 10 Sikov, Berry, Perou (bib52) 2015; 33 Blenman, Marczyk, Karn (bib73) 2022; 28 Xie, Ding, Wang (bib45) 2023 Adams, Schmid, Rugo (bib5) 2017; 35 Kolberg-Liedtke, Schumacher, Erber (bib49) 2022; 82 Im, Lee, Min (bib21) 2022; 82 Carter, Koch, Lauer, Hartkopf (bib61) 2021; 11 Quintana, Peg, Prat (bib60) 2021; 148 Erber, Kolberg, Schumacher (bib26) 2023; 41 Bassez, Vos, Van Dyck (bib31) 2021; 27 Adams, Loi, Toppmeyer (bib11) 2019; 30 Conte, Dieci, Bisagni (bib64) 2020; 38 Dirix, Takacs, Jerusalem (bib7) 2018; 167 Tarhini, Lin, Lin (bib46) 2018; 6 Kolberg, Schumacher, Erber (bib75) 2023; 83 Huebner, Rübner, Schneeweiss (bib32) 2023; 41 Emens, Cruz, Eder (bib9) 2019; 5 Abed, Calapre, Bowyer, Millward, Gray (bib47) 2021; 16 Szekely, Bossuyt, Li (bib12) 2018; 29 Dieci, Radosevic-Robin, Fineberg (bib44) 2018; 52 Schmid, Cortes, Pusztai (bib14) 2020; 382 Diab, McArthur, Solomon (bib68) 2014; 32 Shatsky, Trivedi, Omene (bib53) 2024; 42 Wang, Zhou, Yang (bib13) 2019; 5 Blank, Rozeman, Fanchi (bib62) 2018; 24 Nanda, Chow, Dees (bib8) 2016; 34 Adams, Schmid, Rugo (bib10) 2019; 30 Page, Yuan, Redmond (bib70) 2016; 4 Adams, Gray, Demaria (bib55) 2014; 32 Vos, Lambein, Richard (bib72) 2022; 82 Metzger-Filho, Tutt, de Azambuja (bib1) 2012; 30 Nanda, Liu, Yau (bib35) 2020; 6 Dieci (10.1016/j.esmoop.2024.103713_bib44) 2018; 52 Adams (10.1016/j.esmoop.2024.103713_bib10) 2019; 30 Kolberg (10.1016/j.esmoop.2024.103713_bib76) 2024; 84 Stecklein (10.1016/j.esmoop.2024.103713_bib25) 2023; 41 Pan (10.1016/j.esmoop.2024.103713_bib71) 2024; 5 Page (10.1016/j.esmoop.2024.103713_bib41) 2023; 41 Erber (10.1016/j.esmoop.2024.103713_bib26) 2023; 41 McArthur (10.1016/j.esmoop.2024.103713_bib42) 2016; 22 Huebner (10.1016/j.esmoop.2024.103713_bib32) 2023; 41 Loibl (10.1016/j.esmoop.2024.103713_bib18) 2022; 33 Blenman (10.1016/j.esmoop.2024.103713_bib73) 2022; 28 Virassamy (10.1016/j.esmoop.2024.103713_bib74) 2023; 41 Turner (10.1016/j.esmoop.2024.103713_bib66) 2023; 34 Verma (10.1016/j.esmoop.2024.103713_bib15) 2016; 18 Yang (10.1016/j.esmoop.2024.103713_bib48) 2018; 29 Loi (10.1016/j.esmoop.2024.103713_bib22) 2022; 8 Shatsky (10.1016/j.esmoop.2024.103713_bib53) 2024; 42 Conte (10.1016/j.esmoop.2024.103713_bib64) 2020; 38 Adams (10.1016/j.esmoop.2024.103713_bib11) 2019; 30 Wang (10.1016/j.esmoop.2024.103713_bib13) 2019; 5 Gianni (10.1016/j.esmoop.2024.103713_bib37) 2022; 33 Loibl (10.1016/j.esmoop.2024.103713_bib30) 2019; 79 Schmid (10.1016/j.esmoop.2024.103713_bib23) 2020; 31 McArthur (10.1016/j.esmoop.2024.103713_bib57) 2019; 79 Césaire (10.1016/j.esmoop.2024.103713_bib20) 2018; 19 Loibl (10.1016/j.esmoop.2024.103713_bib40) 2019; 30 Arnaout (10.1016/j.esmoop.2024.103713_bib54) 2024; 84 Masuda (10.1016/j.esmoop.2024.103713_bib4) 2017; 376 Kolberg-Liedtke (10.1016/j.esmoop.2024.103713_bib49) 2022; 82 Metzger-Filho (10.1016/j.esmoop.2024.103713_bib1) 2012; 30 Schmid (10.1016/j.esmoop.2024.103713_bib2) 2022; 386 Adams (10.1016/j.esmoop.2024.103713_bib5) 2017; 35 Page (10.1016/j.esmoop.2024.103713_bib70) 2016; 4 Sikov (10.1016/j.esmoop.2024.103713_bib52) 2015; 33 Xie (10.1016/j.esmoop.2024.103713_bib45) 2023 Diab (10.1016/j.esmoop.2024.103713_bib68) 2014; 32 Tarhini (10.1016/j.esmoop.2024.103713_bib46) 2018; 6 Spears (10.1016/j.esmoop.2024.103713_bib58) 2023; 41 McArthur (10.1016/j.esmoop.2024.103713_bib27) 2021; 81 Adams (10.1016/j.esmoop.2024.103713_bib55) 2014; 32 Szekely (10.1016/j.esmoop.2024.103713_bib12) 2018; 29 Blank (10.1016/j.esmoop.2024.103713_bib62) 2018; 24 Loibl (10.1016/j.esmoop.2024.103713_bib17) 2019; 30 Karn (10.1016/j.esmoop.2024.103713_bib29) 2020; 31 Emens (10.1016/j.esmoop.2024.103713_bib9) 2019; 5 Tutt (10.1016/j.esmoop.2024.103713_bib3) 2021; 384 Schmid (10.1016/j.esmoop.2024.103713_bib28) 2021; 9 Czajka-Francuz (10.1016/j.esmoop.2024.103713_bib56) 2023; 13 Vos (10.1016/j.esmoop.2024.103713_bib72) 2022; 82 Nanda (10.1016/j.esmoop.2024.103713_bib8) 2016; 34 McArthur (10.1016/j.esmoop.2024.103713_bib63) 2024; 200 Winer (10.1016/j.esmoop.2024.103713_bib6) 2021; 22 Mittendorf (10.1016/j.esmoop.2024.103713_bib38) 2020; 396 Schmid (10.1016/j.esmoop.2024.103713_bib67) 2017; 35 Denkert (10.1016/j.esmoop.2024.103713_bib50) 2015; 33 Dirix (10.1016/j.esmoop.2024.103713_bib7) 2018; 167 Schmid (10.1016/j.esmoop.2024.103713_bib33) 2023; 34 Geyer (10.1016/j.esmoop.2024.103713_bib51) 2022; 33 Carter (10.1016/j.esmoop.2024.103713_bib61) 2021; 11 Abed (10.1016/j.esmoop.2024.103713_bib47) 2021; 16 Quintana (10.1016/j.esmoop.2024.103713_bib60) 2021; 148 Bassez (10.1016/j.esmoop.2024.103713_bib31) 2021; 27 Kolberg (10.1016/j.esmoop.2024.103713_bib75) 2023; 83 Das (10.1016/j.esmoop.2024.103713_bib16) 2020; 4 Voorwerk (10.1016/j.esmoop.2024.103713_bib59) 2019; 25 Nanda (10.1016/j.esmoop.2024.103713_bib35) 2020; 6 Pusztai (10.1016/j.esmoop.2024.103713_bib65) 2018; 78 Page (10.1016/j.esmoop.2024.103713_bib69) 2014; 2 Schmid (10.1016/j.esmoop.2024.103713_bib14) 2020; 382 Sharma (10.1016/j.esmoop.2024.103713_bib24) 2024; 10 Spring (10.1016/j.esmoop.2024.103713_bib36) 2024; 35 Bear (10.1016/j.esmoop.2024.103713_bib43) 2024; 84 Nederlof (10.1016/j.esmoop.2024.103713_bib19) 2022; 33 Im (10.1016/j.esmoop.2024.103713_bib21) 2022; 82 Conte (10.1016/j.esmoop.2024.103713_bib39) 2024; 42 |
References_xml | – volume: 29 start-page: 2232 year: 2018 end-page: 2239 ident: bib12 article-title: Immunological differences between primary and metastatic breast cancer publication-title: Ann Oncol contributor: fullname: Li – volume: 84 start-page: PO1-18 year: 2024 ident: bib43 article-title: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968). Poster Session Abstracts publication-title: Cancer Res contributor: fullname: Bandyopadhyay – volume: 41 start-page: 595 year: 2023 ident: bib26 article-title: Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: a translational analysis of the neoMono trial publication-title: J Clin Oncol contributor: fullname: Schumacher – volume: 81 start-page: PS12 year: 2021 ident: bib27 article-title: Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC) publication-title: Cancer Res contributor: fullname: Karlan – volume: 27 start-page: 820 year: 2021 end-page: 832 ident: bib31 article-title: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer publication-title: Nat Med contributor: fullname: Van Dyck – volume: 41 start-page: 573 year: 2023 ident: bib58 article-title: Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: the INVINCIBLE trial publication-title: J Clin Oncol contributor: fullname: Keyhanian – volume: 6 start-page: 676 year: 2020 end-page: 684 ident: bib35 article-title: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial publication-title: JAMA Oncol contributor: fullname: Yau – volume: 33 start-page: 13 year: 2015 end-page: 21 ident: bib52 article-title: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) publication-title: J Clin Oncol contributor: fullname: Perou – volume: 31 start-page: 569 year: 2020 end-page: 581 ident: bib23 article-title: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study publication-title: Ann Oncol contributor: fullname: Park – volume: 200 year: 2024 ident: bib63 article-title: Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial publication-title: Eur J Cancer contributor: fullname: Saji – volume: 376 start-page: 2147 year: 2017 end-page: 2159 ident: bib4 article-title: Adjuvant capecitabine for breast cancer after preoperative chemotherapy publication-title: N Engl J Med contributor: fullname: Ohtani – volume: 18 start-page: 10 year: 2016 ident: bib15 article-title: Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer publication-title: Breast Cancer Res contributor: fullname: Horgan – volume: 9 start-page: A1 year: 2021 end-page: A1054 ident: bib28 article-title: Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study publication-title: J Immunother Cancer contributor: fullname: Muñoz-Couselo – volume: 82 year: 2022 ident: bib49 article-title: OT2-29-01: neoMono - An adaptive randomized neoadjuvant two arm trial in patients with TNBC comparing a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy. Ongoing Trials Poster Session Abstracts publication-title: Cancer Res contributor: fullname: Erber – volume: 38 year: 2020 ident: bib64 article-title: Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial publication-title: J Clin Oncol contributor: fullname: Bisagni – volume: 41 start-page: 1011 year: 2023 ident: bib32 article-title: RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial publication-title: J Clin Oncol contributor: fullname: Schneeweiss – volume: 83 start-page: PD11 year: 2023 ident: bib75 article-title: PD11-03 - Comparison of a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono. Poster Spotlight Discussion Abstracts publication-title: Cancer Res contributor: fullname: Erber – volume: 33 year: 2022 ident: bib19 article-title: LssBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial publication-title: Ann Oncol contributor: fullname: Bakker – volume: 29 start-page: 311 year: 2018 end-page: 323 ident: bib48 article-title: Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? publication-title: Ann Oncol contributor: fullname: Bitting – volume: 16 start-page: S870 year: 2021 ident: bib47 article-title: Pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy publication-title: J Thorac Oncol contributor: fullname: Gray – volume: 8 start-page: 3 year: 2022 ident: bib22 article-title: Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer publication-title: NPJ Breast Cancer contributor: fullname: Adams – volume: 41 start-page: 585 year: 2023 end-page: 601.e8 ident: bib74 article-title: Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer publication-title: Cancer Cell contributor: fullname: Savas – volume: 32 start-page: 1098 year: 2014 ident: bib68 article-title: A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC) publication-title: J Clin Oncol contributor: fullname: Solomon – volume: 34 year: 2023 ident: bib33 article-title: LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study publication-title: Ann Oncol contributor: fullname: Dent – volume: 4 start-page: 835 year: 2016 end-page: 844 ident: bib70 article-title: Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy publication-title: Cancer Immunol Res contributor: fullname: Redmond – volume: 28 start-page: 2587 year: 2022 end-page: 2597 ident: bib73 article-title: Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in basal-like triple-negative breast cancer publication-title: Clin Cancer Res contributor: fullname: Karn – volume: 19 start-page: 3793 year: 2018 ident: bib20 article-title: Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? publication-title: Int J Mol Sci contributor: fullname: Candéias – volume: 33 start-page: 534 year: 2022 end-page: 543 ident: bib37 article-title: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study publication-title: Ann Oncol contributor: fullname: Egle – volume: 33 start-page: 384 year: 2022 end-page: 394 ident: bib51 article-title: Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial publication-title: Ann Oncol contributor: fullname: Huober – volume: 5 start-page: 291 year: 2024 end-page: 310.e5 ident: bib71 article-title: Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: a window-of-opportunity trial publication-title: Med contributor: fullname: Tang – volume: 382 start-page: 810 year: 2020 end-page: 821 ident: bib14 article-title: Pembrolizumab for early triple-negative breast cancer publication-title: N Engl J Med contributor: fullname: Pusztai – volume: 25 start-page: 920 year: 2019 end-page: 928 ident: bib59 article-title: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial publication-title: Nat Med contributor: fullname: Horlings – volume: 396 start-page: 1090 year: 2020 end-page: 1100 ident: bib38 article-title: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial publication-title: Lancet contributor: fullname: Barrios – volume: 4 start-page: 4653 year: 2020 end-page: 4664 ident: bib16 article-title: Lingering effects of chemotherapy on mature T cells impair proliferation publication-title: Blood Adv contributor: fullname: Barrett – volume: 33 start-page: 983 year: 2015 end-page: 991 ident: bib50 article-title: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers publication-title: J Clin Oncol contributor: fullname: Brase – volume: 22 start-page: 5729 year: 2016 end-page: 5737 ident: bib42 article-title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling publication-title: Clin Cancer Res contributor: fullname: Page – volume: 5 start-page: 1008 year: 2019 end-page: 1019 ident: bib13 article-title: Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis publication-title: JAMA Oncol contributor: fullname: Yang – volume: 10 start-page: 227 year: 2024 end-page: 235 ident: bib24 article-title: Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT Phase 2 clinical trial publication-title: JAMA Oncol contributor: fullname: Yoder – volume: 24 start-page: 1655 year: 2018 end-page: 1661 ident: bib62 article-title: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma publication-title: Nat Med contributor: fullname: Fanchi – volume: 384 start-page: 2394 year: 2021 end-page: 2405 ident: bib3 article-title: Adjuvant olaparib for patients with BRCA1 - or BRCA2 - mutated breast cancer publication-title: N Engl J Med contributor: fullname: Kaufman – volume: 30 start-page: 1279 year: 2019 end-page: 1288 ident: bib17 article-title: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study publication-title: Ann Oncol contributor: fullname: Burchardi – volume: 82 start-page: PD15 year: 2022 ident: bib21 article-title: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer publication-title: Cancer Res contributor: fullname: Min – volume: 34 start-page: 2460 year: 2016 end-page: 2467 ident: bib8 article-title: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study publication-title: J Clin Oncol contributor: fullname: Dees – volume: 79 year: 2019 ident: bib57 article-title: Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC) publication-title: Cancer Res contributor: fullname: Shiao – volume: 33 start-page: 1149 year: 2022 end-page: 1158 ident: bib18 article-title: Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response publication-title: Ann Oncol contributor: fullname: Huober – volume: 30 start-page: 1879 year: 2012 end-page: 1887 ident: bib1 article-title: Dissecting the heterogeneity of triple-negative breast cancer publication-title: J Clin Oncol contributor: fullname: de Azambuja – volume: 41 start-page: 604 year: 2023 ident: bib41 article-title: NeoIRX trial: immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC) publication-title: J Clin Oncol contributor: fullname: Moxon – volume: 35 start-page: 556 year: 2017 ident: bib67 article-title: Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173 publication-title: J Clin Oncol contributor: fullname: Muñoz-Couselo – year: 2024 ident: bib34 article-title: Merck announces phase 3 KEYNOTE-522 trial met its overall survival (OS) endpoint in patients with high-risk early-stage triple negative breast cancer (TNBC) – volume: 148 start-page: 134 year: 2021 end-page: 145 ident: bib60 article-title: Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer publication-title: Eur J Cancer contributor: fullname: Prat – volume: 34 start-page: 200 year: 2023 end-page: 211 ident: bib66 article-title: Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer publication-title: Ann Oncol contributor: fullname: Jenkins – volume: 79 start-page: PD2 year: 2019 ident: bib30 article-title: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial publication-title: Cancer Res contributor: fullname: Karn – volume: 52 start-page: 16 year: 2018 end-page: 25 ident: bib44 article-title: Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on breast cancer publication-title: Semin Cancer Biol contributor: fullname: Fineberg – volume: 386 start-page: 556 year: 2022 end-page: 567 ident: bib2 article-title: Event-free survival with pembrolizumab in early triple-negative breast cancer publication-title: N Engl J Med contributor: fullname: Dent – volume: 41 start-page: 507 year: 2023 ident: bib25 article-title: Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): biomarker analysis of the NeoPACT trial publication-title: J Clin Oncol contributor: fullname: Staley – volume: 30 start-page: 405 year: 2019 end-page: 411 ident: bib11 article-title: Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study publication-title: Ann Oncol contributor: fullname: Toppmeyer – volume: 167 start-page: 671 year: 2018 end-page: 686 ident: bib7 article-title: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study publication-title: Breast Cancer Res Treat contributor: fullname: Jerusalem – volume: 78 year: 2018 ident: bib65 article-title: OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. Ongoing Clinical Trials publication-title: Cancer Res contributor: fullname: Ganz – volume: 84 start-page: PS16 year: 2024 ident: bib76 article-title: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer – final analysis of the neoadjuvant NeoMono trial publication-title: Cancer Res contributor: fullname: Erber – volume: 5 start-page: 74 year: 2019 end-page: 82 ident: bib9 article-title: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study publication-title: JAMA Oncol contributor: fullname: Eder – volume: 30 start-page: 397 year: 2019 end-page: 404 ident: bib10 article-title: Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study publication-title: Ann Oncol contributor: fullname: Rugo – volume: 31 start-page: 1216 year: 2020 end-page: 1222 ident: bib29 article-title: Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo publication-title: Ann Oncol contributor: fullname: Weber – volume: 2 start-page: P138 year: 2014 ident: bib69 article-title: Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) publication-title: J Immunother Cancer contributor: fullname: Dong – volume: 35 start-page: 293 year: 2024 end-page: 301 ident: bib36 article-title: Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial publication-title: Ann Oncol contributor: fullname: Fell – year: 2023 ident: bib45 article-title: PO3-18-04 - Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: a randomized window-of-opporunity trial publication-title: SABCS Abstract. #PO3-18-04 contributor: fullname: Wang – volume: 22 start-page: 499 year: 2021 end-page: 511 ident: bib6 article-title: Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol contributor: fullname: Im – volume: 13 year: 2023 ident: bib56 article-title: Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy publication-title: Front Oncol contributor: fullname: Mankan – volume: 32 start-page: 2959 year: 2014 end-page: 2967 ident: bib55 article-title: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 publication-title: J Clin Oncol contributor: fullname: Demaria – volume: 42 year: 2024 ident: bib53 article-title: Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: results from the I-SPY2.2 trial publication-title: J Clin Oncol contributor: fullname: Omene – volume: 11 year: 2021 ident: bib61 article-title: Clinical trials of oncolytic viruses in breast cancer publication-title: Front Oncol contributor: fullname: Hartkopf – volume: 30 year: 2019 ident: bib40 article-title: GeparDouze/NSABP B-59: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo publication-title: Ann Oncol contributor: fullname: Rastogi – volume: 6 start-page: 112 year: 2018 ident: bib46 article-title: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire publication-title: J Immunother Cancer contributor: fullname: Lin – volume: 84 start-page: PS16 year: 2024 ident: bib54 article-title: PS16-03 - Intratumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell Necrosis and immunomodulatory effects: a Phase II randomized window-of-opportunity study – the INVINCIBLE trial. Poster Spotlight Abstracts publication-title: Cancer Res contributor: fullname: Hopkins – volume: 35 start-page: 1008 year: 2017 ident: bib5 article-title: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A publication-title: J Clin Oncol contributor: fullname: Rugo – volume: 82 year: 2022 ident: bib72 article-title: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC) publication-title: Cancer Res contributor: fullname: Richard – volume: 42 year: 2024 ident: bib39 article-title: A-BRAVE trial: a phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy publication-title: J Clin Oncol contributor: fullname: Bisagni – volume: 200 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib63 article-title: Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2024.113952 contributor: fullname: McArthur – volume: 10 start-page: 227 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib24 article-title: Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT Phase 2 clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2023.5033 contributor: fullname: Sharma – volume: 41 start-page: 573 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib58 article-title: Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: the INVINCIBLE trial publication-title: J Clin Oncol doi: 10.1200/JCO.2023.41.16_suppl.573 contributor: fullname: Spears – volume: 33 start-page: 384 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib51 article-title: Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.01.009 contributor: fullname: Geyer – volume: 31 start-page: 1216 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib29 article-title: Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.05.015 contributor: fullname: Karn – volume: 5 start-page: 291 issue: 4 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib71 article-title: Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: a window-of-opportunity trial publication-title: Med doi: 10.1016/j.medj.2024.01.015 contributor: fullname: Pan – year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib45 article-title: PO3-18-04 - Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: a randomized window-of-opporunity trial publication-title: SABCS Abstract. #PO3-18-04 contributor: fullname: Xie – volume: 4 start-page: 4653 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib16 article-title: Lingering effects of chemotherapy on mature T cells impair proliferation publication-title: Blood Adv doi: 10.1182/bloodadvances.2020001797 contributor: fullname: Das – volume: 81 start-page: PS12 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib27 article-title: Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC) publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS20-PS12-09 contributor: fullname: McArthur – volume: 41 start-page: 1011 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib32 article-title: RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial publication-title: J Clin Oncol doi: 10.1200/JCO.2023.41.16_suppl.1011 contributor: fullname: Huebner – volume: 6 start-page: 112 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib46 article-title: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0428-5 contributor: fullname: Tarhini – volume: 84 start-page: PS16 issue: suppl 9 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib76 article-title: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer – final analysis of the neoadjuvant NeoMono trial publication-title: Cancer Res contributor: fullname: Kolberg – volume: 82 start-page: PD15 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib21 article-title: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS21-PD15-08 contributor: fullname: Im – volume: 29 start-page: 311 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib48 article-title: Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? publication-title: Ann Oncol doi: 10.1093/annonc/mdx766 contributor: fullname: Yang – volume: 35 start-page: 293 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib36 article-title: Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2023.11.018 contributor: fullname: Spring – volume: 38 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib64 article-title: Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: the A-BRAVE trial publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.TPS598 contributor: fullname: Conte – volume: 22 start-page: 499 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib6 article-title: Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30754-3 contributor: fullname: Winer – volume: 34 start-page: 200 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib66 article-title: Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.11.005 contributor: fullname: Turner – volume: 6 start-page: 676 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib35 article-title: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.6650 contributor: fullname: Nanda – volume: 30 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib40 article-title: GeparDouze/NSABP B-59: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo publication-title: Ann Oncol doi: 10.1093/annonc/mdz097.014 contributor: fullname: Loibl – volume: 42 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib53 article-title: Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: results from the I-SPY2.2 trial publication-title: J Clin Oncol doi: 10.1200/JCO.2024.42.17_suppl.LBA501 contributor: fullname: Shatsky – volume: 82 issue: suppl 4 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib49 article-title: OT2-29-01: neoMono - An adaptive randomized neoadjuvant two arm trial in patients with TNBC comparing a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy. Ongoing Trials Poster Session Abstracts publication-title: Cancer Res contributor: fullname: Kolberg-Liedtke – volume: 386 start-page: 556 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib2 article-title: Event-free survival with pembrolizumab in early triple-negative breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2112651 contributor: fullname: Schmid – volume: 35 start-page: 556 year: 2017 ident: 10.1016/j.esmoop.2024.103713_bib67 article-title: Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.556 contributor: fullname: Schmid – volume: 33 start-page: 1149 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib18 article-title: Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.07.1940 contributor: fullname: Loibl – volume: 8 start-page: 3 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib22 article-title: Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer publication-title: NPJ Breast Cancer doi: 10.1038/s41523-021-00362-1 contributor: fullname: Loi – volume: 33 start-page: 983 year: 2015 ident: 10.1016/j.esmoop.2024.103713_bib50 article-title: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.1967 contributor: fullname: Denkert – volume: 41 start-page: 595 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib26 publication-title: J Clin Oncol doi: 10.1200/JCO.2023.41.16_suppl.595 contributor: fullname: Erber – volume: 41 start-page: 507 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib25 article-title: Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): biomarker analysis of the NeoPACT trial publication-title: J Clin Oncol doi: 10.1200/JCO.2023.41.16_suppl.507 contributor: fullname: Stecklein – volume: 31 start-page: 569 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib23 article-title: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.01.072 contributor: fullname: Schmid – volume: 33 start-page: 534 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib37 article-title: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.02.004 contributor: fullname: Gianni – volume: 13 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib56 article-title: Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy publication-title: Front Oncol doi: 10.3389/fonc.2023.1200646 contributor: fullname: Czajka-Francuz – volume: 41 start-page: 604 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib41 article-title: NeoIRX trial: immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC) publication-title: J Clin Oncol doi: 10.1200/JCO.2023.41.16_suppl.604 contributor: fullname: Page – volume: 35 start-page: 1008 year: 2017 ident: 10.1016/j.esmoop.2024.103713_bib5 article-title: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.1008 contributor: fullname: Adams – volume: 30 start-page: 1279 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib17 article-title: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study publication-title: Ann Oncol doi: 10.1093/annonc/mdz158 contributor: fullname: Loibl – volume: 30 start-page: 1879 year: 2012 ident: 10.1016/j.esmoop.2024.103713_bib1 article-title: Dissecting the heterogeneity of triple-negative breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.2010 contributor: fullname: Metzger-Filho – volume: 382 start-page: 810 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib14 article-title: Pembrolizumab for early triple-negative breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1910549 contributor: fullname: Schmid – volume: 24 start-page: 1655 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib62 article-title: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma publication-title: Nat Med doi: 10.1038/s41591-018-0198-0 contributor: fullname: Blank – volume: 33 start-page: 13 year: 2015 ident: 10.1016/j.esmoop.2024.103713_bib52 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.0572 contributor: fullname: Sikov – volume: 19 start-page: 3793 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib20 article-title: Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? publication-title: Int J Mol Sci doi: 10.3390/ijms19123793 contributor: fullname: Césaire – volume: 2 start-page: P138 year: 2014 ident: 10.1016/j.esmoop.2024.103713_bib69 article-title: Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) publication-title: J Immunother Cancer doi: 10.1186/2051-1426-2-S3-P138 contributor: fullname: Page – volume: 28 start-page: 2587 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib73 article-title: Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in basal-like triple-negative breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-3215 contributor: fullname: Blenman – volume: 84 start-page: PS16 issue: suppl 9 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib54 article-title: PS16-03 - Intratumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell Necrosis and immunomodulatory effects: a Phase II randomized window-of-opportunity study – the INVINCIBLE trial. Poster Spotlight Abstracts publication-title: Cancer Res contributor: fullname: Arnaout – volume: 79 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib57 article-title: Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC) publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS18-P2-09-07 contributor: fullname: McArthur – volume: 34 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib33 article-title: LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study publication-title: Ann Oncol doi: 10.1016/j.annonc.2023.10.008 contributor: fullname: Schmid – volume: 83 start-page: PD11 issue: suppl 5 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib75 publication-title: Cancer Res contributor: fullname: Kolberg – volume: 82 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib72 article-title: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC) publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS21-P2-08-23 contributor: fullname: Vos – volume: 29 start-page: 2232 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib12 article-title: Immunological differences between primary and metastatic breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdy399 contributor: fullname: Szekely – volume: 16 start-page: S870 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib47 article-title: Pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2021.08.075 contributor: fullname: Abed – volume: 42 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib39 article-title: A-BRAVE trial: a phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2024.42.17_suppl.LBA500 contributor: fullname: Conte – volume: 34 start-page: 2460 year: 2016 ident: 10.1016/j.esmoop.2024.103713_bib8 article-title: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study publication-title: J Clin Oncol doi: 10.1200/JCO.2015.64.8931 contributor: fullname: Nanda – volume: 32 start-page: 1098 year: 2014 ident: 10.1016/j.esmoop.2024.103713_bib68 article-title: A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC) publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.1098 contributor: fullname: Diab – volume: 11 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib61 article-title: Clinical trials of oncolytic viruses in breast cancer publication-title: Front Oncol doi: 10.3389/fonc.2021.803050 contributor: fullname: Carter – volume: 52 start-page: 16 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib44 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2017.10.003 contributor: fullname: Dieci – volume: 22 start-page: 5729 year: 2016 ident: 10.1016/j.esmoop.2024.103713_bib42 article-title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0190 contributor: fullname: McArthur – volume: 376 start-page: 2147 year: 2017 ident: 10.1016/j.esmoop.2024.103713_bib4 article-title: Adjuvant capecitabine for breast cancer after preoperative chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1612645 contributor: fullname: Masuda – volume: 396 start-page: 1090 year: 2020 ident: 10.1016/j.esmoop.2024.103713_bib38 article-title: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31953-X contributor: fullname: Mittendorf – volume: 9 start-page: A1 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib28 article-title: Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study publication-title: J Immunother Cancer contributor: fullname: Schmid – volume: 5 start-page: 74 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib9 article-title: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.4224 contributor: fullname: Emens – volume: 32 start-page: 2959 year: 2014 ident: 10.1016/j.esmoop.2024.103713_bib55 article-title: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.55.0491 contributor: fullname: Adams – volume: 167 start-page: 671 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib7 article-title: Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4537-5 contributor: fullname: Dirix – volume: 148 start-page: 134 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib60 article-title: Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2021.01.037 contributor: fullname: Quintana – volume: 384 start-page: 2394 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib3 article-title: Adjuvant olaparib for patients with BRCA1 - or BRCA2 - mutated breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2105215 contributor: fullname: Tutt – volume: 30 start-page: 397 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib10 article-title: Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study publication-title: Ann Oncol doi: 10.1093/annonc/mdy517 contributor: fullname: Adams – volume: 5 start-page: 1008 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib13 article-title: Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.0393 contributor: fullname: Wang – volume: 18 start-page: 10 year: 2016 ident: 10.1016/j.esmoop.2024.103713_bib15 article-title: Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer publication-title: Breast Cancer Res doi: 10.1186/s13058-015-0669-x contributor: fullname: Verma – volume: 30 start-page: 405 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib11 article-title: Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study publication-title: Ann Oncol doi: 10.1093/annonc/mdy518 contributor: fullname: Adams – volume: 25 start-page: 920 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib59 article-title: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial publication-title: Nat Med doi: 10.1038/s41591-019-0432-4 contributor: fullname: Voorwerk – volume: 4 start-page: 835 year: 2016 ident: 10.1016/j.esmoop.2024.103713_bib70 article-title: Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0013 contributor: fullname: Page – volume: 78 issue: suppl 4 year: 2018 ident: 10.1016/j.esmoop.2024.103713_bib65 publication-title: Cancer Res contributor: fullname: Pusztai – volume: 79 start-page: PD2 year: 2019 ident: 10.1016/j.esmoop.2024.103713_bib30 article-title: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial publication-title: Cancer Res doi: 10.1158/1538-7445.SABCS18-PD2-07 contributor: fullname: Loibl – volume: 41 start-page: 585 year: 2023 ident: 10.1016/j.esmoop.2024.103713_bib74 article-title: Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.01.004 contributor: fullname: Virassamy – volume: 84 start-page: PO1-18 issue: suppl 9 year: 2024 ident: 10.1016/j.esmoop.2024.103713_bib43 article-title: Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968). Poster Session Abstracts publication-title: Cancer Res contributor: fullname: Bear – volume: 27 start-page: 820 year: 2021 ident: 10.1016/j.esmoop.2024.103713_bib31 article-title: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer publication-title: Nat Med doi: 10.1038/s41591-021-01323-8 contributor: fullname: Bassez – volume: 33 year: 2022 ident: 10.1016/j.esmoop.2024.103713_bib19 article-title: LssBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.08.007 contributor: fullname: Nederlof |
SSID | ssj0001742056 |
Score | 2.323407 |
SecondaryResourceType | review_article |
Snippet | Patients with triple-negative breast cancer (TNBC) have a relatively poor clinical outcome. The immune checkpoint inhibitor (ICI) pembrolizumab combined with... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 103713 |
SubjectTerms | immune checkpoint inhibitors PD-L1 triple-negative breast cancer tumor-infiltrating lymphocytes window of opportunity |
Title | Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer |
URI | https://dx.doi.org/10.1016/j.esmoop.2024.103713 https://www.ncbi.nlm.nih.gov/pubmed/39357122 https://www.proquest.com/docview/3112526427/abstract/ |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgL4s2Wh4zEbZUoTex4c6wQqEIsHPqgN8uvQIpIVu3upb-eGdt50AdQLlFk7VqO59vZbybzeQh5WxoDUXLmEqZYkbASYLyoSyRy3FluszroK5afy71D9vGYH4-vYry6ZK1Tc36lruR_rApjYFdUyd7AssOkMAD3YF-4goXh-k82_goBded1J90KefSmRU7tG3FE1VqD8g83B8uYH6uuabEhwPdGN77HDpY4nmKiPWndt3AAuMYa9TWWgplYtttn7feXX-bYamvMlMJsKijKdtMhUYMNJ7zzSPeHwaPG-rYC80_p6Im9izlKp1mHnA31a9E55UDLEpHFbIW7Yix612oKomziKlGgGGSol7x4SCicpO7sZ9fhoaI5S8eP_35o9oU_s6HEsK9eO5FhFomzyDDLbXInFxXnkwjcp-QEg0fw7Qj7J-nFlr4i8PJyriMz1wUrnrQcPCD3Y7RBdwN0HpJbrn1E7i5jPcVjIgOCaFfTCYJoQBBFBNGAIDoiiI4Iglt6AUE0IIgGBD0hhx_eH7zbS2LLjcTAYxVJwa3OarVwQP0qw0yldFbZHVM6y4Aa4mtiq3kFpFMJzg3LnEIZixXaLUxRL4qnZKvtWvecUOuMrrVzsNGMCVHqQmlWscKprFR1Vs1I0u-dXIWTVeSfjDYjot9gGdlhYH0SYPOXb77p7SHBeeIbMdW6bnMmC4g2OIQEuZiRZ8FQw1pQsy528nz7hut8Qe6NP5iXZGt9unGvgLiu9WsPt19llJc7 |
link.rule.ids | 315,786,790,870,27955,27956 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Window+of+opportunity+trials+with+immune+checkpoint+inhibitors+in+triple-negative+breast+cancer&rft.jtitle=ESMO+open&rft.au=Quintana%2C+A.&rft.au=Saini%2C+K.S.&rft.au=Vidal%2C+L.&rft.au=Peg%2C+V.&rft.date=2024-10-01&rft.issn=2059-7029&rft.eissn=2059-7029&rft.volume=9&rft.issue=10&rft.spage=103713&rft_id=info:doi/10.1016%2Fj.esmoop.2024.103713&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_esmoop_2024_103713 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-7029&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-7029&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-7029&client=summon |